Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hatch, Cannon Oppose Risk-Benefit For Ephedra; Experts Discuss NPA Brief

This article was originally published in The Tan Sheet

Executive Summary

"Nutritional supplements are not drugs and should not be regulated as such," Rep. Chris Cannon, R-Utah, said in response to inquiries about the possible review of the risk-benefit standard by the Supreme Court

You may also be interested in...



NPA To Supreme Court: Risk-Benefit Standard Would “Unravel” DSHEA

The National Products Association filed a brief with the Supreme Court April 6 in support of Nutraceutical Corp.'s petition for review of an appellate court decision upholding FDA's use of a risk-benefit standard to determine product adulteration

Will Nutraceutical Succeed In Asking Supreme Court To Review Ephedra Ban?

According to food and drug lawyer Marc Ullman, it is unlikely the Supreme Court will review the 10th Circuit Court of Appeals decision affirming FDA's ban of ephedra in dietary supplements

FDA Gets Green Light For Risk-Benefit Analysis From Ephedra Ruling

An appellate court decision upholding FDA's ban of ephedra "will embolden FDA to challenge products that have a bad safety profile," according to Scott Bass, a food and drug law expert and partner at Sidley Austin (Washington, DC)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel